casodex 150 mg filmovertrukne tabletter
laboratoires juvisé pharmaceuticals - bicalutamid - filmovertrukne tabletter - 150 mg
faslodex
astrazeneca ab - fulvestrant - bryst neoplasmer - endokrine terapi, anti-østrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i præ - eller perimenopausal kvinder, kombinationen behandling med palbociclib bør kombineres med en luteiniserende hormon releasing hormon (lhrh) agonist.
nasonex 50 mikrogram/dosis næsespray, suspension
n.v. organon - mometasonfuroat - næsespray, suspension - 50 mikrogram/dosis
cilodex 3+1 mg/ml øredråber, suspension
infectopharm gmbh - ciprofloxacinhydrochlorid (monohydrat), dexamethason - øredråber, suspension - 3+1 mg/ml
cilodex 3+1 mg/ml øredråber, suspension
paranova danmark a/s - ciprofloxacinhydrochlorid (monohydrat), dexamethason - øredråber, suspension - 3+1 mg/ml
cilodex 3+1 mg/ml øredråber, suspension
orifarm a/s - ciprofloxacinhydrochlorid (monohydrat), dexamethason - øredråber, suspension - 3+1 mg/ml
cilodex 3+1 mg/ml øredråber, suspension
nordic prime aps - ciprofloxacinhydrochlorid (monohydrat), dexamethason - øredråber, suspension - 3+1 mg/ml
pasorex 20 mg filmovertrukne tabletter
ratiopharm gmbh - paroxetinhydrochlorid anhydrat - filmovertrukne tabletter - 20 mg
mometason "mg pharma" 50 mikrogram/dosis næsespray, suspension
mg pharma - mometasonfuroat monohydrat - næsespray, suspension - 50 mikrogram/dosis
fulvestrant mylan
mylan pharmaceuticals limited - fulvestrant - bryst neoplasmer - endokrine terapi - fulvestrant er indiceret til behandling af østrogen receptor positiv, lokalt fremskreden eller metastatisk brystkræft hos postmenopausale kvinder:ikke tidligere behandlet med endokrin terapi, orwith disease, tilbagefald eller efter adjuverende anti-østrogen behandling eller af sygdomsprogression på antiøstrogen terapi.